[Dupilumab (chronic rhinosinusitis with nasal polyposis) - Benefit assessment according to §35a Social Code Book V]
Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen
Record ID 32018003660
German
Original Title:
Dupilumab (chronische Rhinosinusitis mit Nasenpolypen) - Nutzenbewertung gemäß § 35a SGB V
Details
Project Status:
Completed
URL for project:
https://www.iqwig.de/projekte/a19-96.html
Year Published:
2020
URL for published report:
https://www.iqwig.de/download/A19-96_Dupilumab_Nutzenbewertung-35a-SGB-V_V1-0.pdf
English language abstract:
There is no English language summary available
Publication Type:
Full HTA
Country:
Germany
MeSH Terms
- Nasal Polyps
- Rhinosinusitis
- Antibodies, Monoclonal, Humanized
Keywords
- Dupilumab
- Sinusitis
- Benefit Assessment
- NCT02912468
- NCT02898454
Contact
Organisation Name:
Institute for Quality and Efficiency in Health Care (IQWiG)
Contact Address:
IQWiG, Siegburger Str. 237, 50679 Cologne, GERMANY, Tel: +49(0)221-35685, Fax: +49(0)221-356851
Contact Email:
berichte@iqwig.de
Copyright:
Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.